On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...
Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on March 6 and set a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback